Revolution Medicines
RVMD
514 hedge funds and large institutions have $19.1B invested in Revolution Medicines in 2026 Q1 according to their latest regulatory filings, with 173 funds opening new positions, 164 increasing their positions, 127 reducing their positions, and 39 closing their positions.
344% more first-time investments, than exits
New positions opened: 173 | Existing positions closed: 39
39% more funds holding in top 10
Funds holding in top 10: 33 → 46 (+13)
33% more funds holding
Funds holding: 386 → 514 (+128)
29% more repeat investments, than reductions
Existing positions increased: 164 | Existing positions reduced: 127
20% more capital invested
Capital invested by funds: $15.9B → $19.1B (+$3.19B)
3.04% less ownership
Funds ownership: 103.09% → 100.05% (-3%)
36% less call options, than puts
Call options by funds: $326M | Put options by funds: $513M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$330M |
| 2 |
BlackRock
New York
|
+$231M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$223M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$210M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$177M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$350M |
| 2 |
Janus Henderson Group
London,
|
-$256M |
| 3 |
GA
General Atlantic
New York
|
-$213M |
| 4 |
LC
Lunate Capital
Al Maryah Island, Abu Dhabi,
United Arab Emirates
|
-$166M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$155M |
RVMD Hedge Fund Activity: Q1 2026 in Review
514 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q1 2026, worth a combined $19.1B — up 20% from $15.9B a quarter earlier.
Buyers outnumbered sellers: 173 funds opened new RVMD positions and 39 closed out — a net gain of 134 holders — while 164 added to existing stakes and 127 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $330M. The largest seller was Bellevue Group, cutting an estimated $350M.
- 514 institutional investors held Revolution Medicines (RVMD) as of Q1 2026, up from 386 in Q4 2025.
- Funds reported $19.1B of Revolution Medicines stock for Q1 2026, up 20% quarter-over-quarter.
- 173 funds opened new Revolution Medicines positions in Q1 2026 and 39 closed out, a net change of +134 holders.
- The largest Revolution Medicines buyer in Q1 2026 was Adage Capital Partners, an estimated $330M added.
- The largest Revolution Medicines seller in Q1 2026 was Bellevue Group, an estimated $350M sold.
Based on aggregated 13F filings for Q1 2026.